Polymorphic variants of SLC6A4 and TPH1 genes as predictors of sertraline efficacy and safety in patients with mixed anxiety-depressive disorder: a pilot study

In an attempt to improve the efficacy of antidepressants, pharmacogenetic studies of polymorphic variants of genes involved in the pharmacodynamics of selective serotonin reuptake inhibitors are being conducted worldwide. This study examined the relationship between polymorphic variants of the serotonergic neurotransmission genes rs4795541 of the SLC6A4 gene and rs1800532 of the TPH1 gene and the response to sertraline therapy in patients with mixed anxiety-depressive disorder (F 41.2) from the Republic of Bashkortostan. Patients took sertraline for 6 weeks. The effectiveness of therapy was assessed at baseline and after 2, 4 and 6 weeks using standard psychometric scales. All patients underwent blood sampling with subsequent genotyping. Statistical processing was performed in the SPSS Statistics v. 13.0 program. It was revealed that the rs4795541*L/L and rs7997012*A/A genotypes can be considered as markers of low efficacy of sertraline therapy. The obtained results confirm the hypothesis about the influence of polymorphisms of the studied genes on the pharmacogenetics of sertraline and emphasize the need for further research.